OREM, Utah, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Reflect Scientific Inc. (OTCQB: RSCF), a leading innovator in cryogenic technology, announced…
Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9…
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative…
XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now…
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.REC-3964 represents a novel, non-antibiotic approach with a unique mechanism…
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"),…
RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing…
Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute…
Dallas, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing,…
Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure…